Test Code CNES Peripheral Nervous System Comprehensive Neuropathy, Autoimmune Evaluation, Serum
Ordering Guidance
Multiple neurological phenotype-specific autoimmune/paraneoplastic evaluations are available. For more information as well as phenotype-specific testing options, refer to Autoimmune Neurology Test Ordering Guide.
For a list of antibodies performed with each evaluation, see Autoimmune Neurology Antibody Matrix.
Specimen Required
Patient Preparation: For optimal antibody detection, specimen collection is recommended to occur before starting immunosuppressant medication or intravenous immunoglobulin (IVIg) treatment.
Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Collection Container/Tube:
Preferred: Red top
Acceptable: Serum gel
Submission Container/Tube: Plastic vial
Specimen Volume: 3 mL Serum
Collection Instructions: Centrifuge and aliquot serum into a plastic vial.
Profile Information
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| CNEI | Comprehensive Neuropathy Interp, S | No | Yes |
| AMPHS | Amphiphysin Ab, S | No | Yes |
| AGN1S | Anti-Glial Nuclear Ab, Type 1 | No | Yes |
| ANN1S | Anti-Neuronal Nuclear Ab, Type 1 | No | Yes |
| ANN3S | Anti-Neuronal Nuclear Ab, Type 3 | No | Yes |
| APBIS | AP3B2 IFA, S | No | Yes |
| CS1CS | CASPR1-IgG CBA, S | No | Yes |
| CS2CS | CASPR2-IgG CBA, S | No | Yes |
| CONCS | Contactin-1 IgG CBA, S | No | Yes |
| CRMS | CRMP-5-IgG, S | No | Yes |
| GQ1ES | GQ1b-IgG ELISA, S | Yes | Yes |
| IGG_D | IgG Disialo. GD1b | No | Yes |
| IGG_M | IgG Monos. GM1 | No | Yes |
| IG5CS | IgLON5 CBA, S | No | Yes |
| IGM_D | IgM Disialo. GD1b | No | Yes |
| IGM_M | IgM Monos. GM1 | No | Yes |
| LG1CS | LGI1-IgG CBA, S | No | Yes |
| MAGES | MAG IgM, S | Yes | Yes |
| NF4FS | Neurofascin-155 IgG4, S | No | Yes |
| PCAB2 | Purkinje Cell Cytoplasmic Ab Type 2 | No | Yes |
Reflex Tests
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| AGNBS | AGNA-1 Immunoblot, S | No | No |
| AGNTS | AGNA-1 Titer, S | No | No |
| APHTS | Amphiphysin Ab Titer, S | No | No |
| AMIBS | Amphiphysin Immunoblot, S | No | No |
| AN1BS | ANNA-1 Immunoblot, S | No | No |
| AN1TS | ANNA-1 Titer, S | No | No |
| AN2BS | ANNA-2 Immunoblot, S | No | No |
| AN3TS | ANNA-3 Titer, S | No | No |
| APBCS | AP3B2 CBA, S | No | No |
| APBTS | AP3B2 IFA Titer, S | No | No |
| CRMTS | CRMP-5-IgG Titer, S | No | No |
| CRMWS | CRMP-5-IgG Western Blot, S | No | No |
| IGDTS | IgG Disialo GD1b Titer, S | No | No |
| IGMTS | IgG Monos GM1 Titer, S | No | No |
| IG5TS | IgLON5 IFA Titer, S | No | No |
| IMDTS | IgM Disialo GD1b Titer, S | No | No |
| IMMTS | IgM Monos GM1 Titer, S | No | No |
| MP1BS | MAP1B Immunoblot, S | No | No |
| PC2TS | PCA-2 Titer, S | No | No |
Testing Algorithm
To assess the probability of your patient having chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) vs mimic disorders, see the Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) calculator.
If the indirect immunofluorescence assay (IFA) patterns suggest amphiphysin antibody, then the amphiphysin antibody IFA titer and amphiphysin antibody immunoblot will be performed at an additional charge.
If the IFA patterns suggest antiglial nuclear antibody-1 (AGNA-1), then the AGNA-1 antibody IFA titer and AGNA-1 antibody immunoblot will be performed at an additional charge.
If the IFA patterns suggest antineuronal nuclear antibody type 1 (ANNA-1), then the ANNA-1 IFA titer, ANNA-1 immunoblot, and ANNA-2 immunoblot will be performed at an additional charge.
If the client requests or the IFA pattern suggests ANNA-3 antibody, then the ANNA-3 IFA titer will be performed at an additional charge.
If the IFA patterns suggest collapsin response-mediator protein-5 (CRMP-5)-IgG, then the CRMP-5 antibody IFA titer and CRMP-5 antibody Western blot will be performed at an additional charge.
Screening tests are performed for IgG and IgM antibodies to GM1 and GD1b. If positive, the appropriate titer assay will be performed at an additional charge.
If the IFA pattern suggests PCA-2 antibody, then the PCA-2 antibody IFA titer and MAP1B immunoblot will be performed at an additional charge.
For more information see:
Special Instructions
Method Name
CNEI: Technical Interpretation
CS1CS, CS2CS, CONCS, IG5CS, LG1CS, APBCS: Cell Binding Assay (CBA)
GQ1ES, IGG_D, IGG_M, IGM_D, IGM_M, MAGES, IGDTS, IGMTS, IMDTS, IMMTS: Enzyme-Linked Immunosorbent Assay (ELISA)
NF4FS: Flow Cytometry
AMPHS, AGN1S, ANN1S, ANN3S, APBIS, CRMS, PCAB2, AGNTS, APHTS, AN1TS, AN3TS, APBTS, CRMTS, IG5TS, PC2TS: Indirect Immunofluorescence Assay (IFA)
CRMWS: Western Blot (WB)
AGNBS, AMIBS, AN1BS, AN2BS, MP1BS: Immunoblot (IB)
Specimen Type
SerumSpecimen Minimum Volume
Serum: 2 mL
Specimen Stability Information
| Specimen Type | Temperature | Time |
|---|---|---|
| Serum | Refrigerated (preferred) | 28 days |
| Frozen | 28 days | |
| Ambient | 72 hours |
Reject Due To
| Gross hemolysis | Reject |
| Gross lipemia | Reject |
| Gross icterus | Reject |
Day(s) Performed
Monday through Sunday
Performing Laboratory
Mayo Clinic Laboratories in Rochester